India's Orphan Drug Potential: 1,004 Rare Disorders, $100,000+ Treatments Await Solutions
GS2Polity · Governance · IR· Health policy & public health· Prelims + Mains·
Orphan drugs and healthcare accessibility: a GS2 Social Justice and Public Health case study.
Why in news
The article highlights India's potential to become a global hub for orphan drug manufacturing to address 1,004 reported rare genetic disorders, proposing policy incentives to overcome high treatment costs.
Background
India reports 1,004 rare genetic disorders with annual treatment costs exceeding $100,000. The Orphan Drug Act of 1983 provides tax breaks and market exclusivity to incentivize development.
Facts for Prelims
- Act / BillOrphan Drug Act: enacted in 1983 to provide tax breaks and market exclusivity for rare disease drugs
- FactIndia supports rare disease patients with subsidies up to Rs 50 lakh
- FactU.S. approved 1,122 orphan drugs post-Act implementation by 2022
Prelims practice question
With reference to orphan drugs and rare genetic disorders in India, consider the following statements:
- India has reported a total of 1,004 rare genetic disorders.
- The Orphan Drug Act of 1983 provides market exclusivity and tax breaks to developers.
- India supports rare disease patients for costs up to Rs 1 crore.
Which of the statements given above is/are correct?
- (a)1 only
- (b)2 only
- (c)1 and 2 only
- (d)1 and 3 only
Show answer
Answer: (c) 1 and 2 only — Statements 1 and 2 are correct. Statement 3 is incorrect: India supports rare disease patients up to Rs 50 lakh.
For Mains
Q. Examine the structural and financial barriers in India's pharmaceutical sector that hinder the development of affordable orphan drugs for rare genetic disorders.
Dimensions to cover in your answer
- Market failure: High R&D costs and small patient pools deter private investment without robust state-led incentives
- Regulatory bottleneck: Complexities in conducting clinical trials for rare diseases and manufacturing specialized drugs
- Affordability gap: High annual treatment costs exceeding $100,000 necessitating government-backed insurance or subsidies
Keywords: Orphan Drugs · Rare Diseases · Pharmaceutical Manufacturing · Market Exclusivity · Clinical Trials · Public Health Policy
More Social Justice notes
- Keralam government plans new Bill to make private health care more affordable · 6 October 2026
- Tamil Nadu allocates ₹812 crore to provide gold and silk sarees for eligible brides · 6 October 2026
- Karnataka to reserve 2% of government jobs for athletes across 34 disciplines · 5 October 2026
- Nara Lokesh orders 1,000 Andhra Pradesh schools to reach five-star status by 2029 · 5 October 2026
- Karnataka to use ₹2,000 crore ADB loan to strengthen 500 public schools · 5 October 2026
- KSRTC to host vending machines and incinerators at 14 terminals for menstrual needs · 5 October 2026
Something wrong, or something missing?
Spotted a mistake in a note, or want a topic, format or PDF that would help your preparation? Write to us. We read every mail and fix errors fast.
This note is generated automatically from SatyaDheesh's news feed and mapped to the UPSC CSE syllabus. Check facts against the original report or PIB before using them in an answer.